Abivax Company Profile, Contacts & Intelligence

Abivax Overview

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease. Obefazimod is an investigational, orally administered, once-daily therapy, which we believe has the potential to be a differentiated treatment option for inflammatory bowel diseases. It is the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. If approved, this therapy has the potential to establish a new therapeutic class currently being referred to as miR-124 enhancers.

Headquarters

Paris, Fr

Website

abivax.com

Industry

Biotechnology

Founded

2013

Phone Number

Available in AeroLeads

Company Email

Available in AeroLeads

Abivax Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

Abivax People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Abivax Workforce Composition

Seniority breakdown across 14 visible profiles.

Compare Similar Companies to Abivax

Explore companies in related markets and compare their industry and employee estimates.